Hecht D - Search Results

1

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.

Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Pockros PJ, et al. Among authors: hecht d. Hepatology. 2007 Aug;46(2):324-9. doi: 10.1002/hep.21664. Hepatology. 2007. PMID: 17654603 Clinical Trial.

2

Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells.

Bernatchez JA, Coste M, Beck S, Wells GA, Luna LA, Clark AE, Zhu Z, Hecht D, Rich JN, Sohl CD, Purse BW, Siqueira-Neto JL. Bernatchez JA, et al. Among authors: hecht d. Viruses. 2019 Apr 20;11(4):365. doi: 10.3390/v11040365. Viruses. 2019. PMID: 31010044 Free PMC article.

3

Structure-based design of guanosine analogue inhibitors targeting GTP cyclohydrolase IB towards a new class of antibiotics.

Samaan GN, Paranagama N, Haque A, Hecht DA, Swairjo MA, Purse BW. Samaan GN, et al. Bioorg Med Chem Lett. 2020 Jan 15;30(2):126818. doi: 10.1016/j.bmcl.2019.126818. Epub 2019 Nov 12. Bioorg Med Chem Lett. 2020. PMID: 31771800 Free PMC article.

4

Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase.

Ortiz MA, Michaels H, Molina B, Toenjes S, Davis J, Marconi GD, Hecht D, Gustafson JL, Piedrafita FJ, Nefzi A. Ortiz MA, et al. Among authors: hecht d. Bioorg Med Chem Lett. 2020 May 1;30(9):127108. doi: 10.1016/j.bmcl.2020.127108. Epub 2020 Mar 17. Bioorg Med Chem Lett. 2020. PMID: 32192797

5

A novel in silico approach to drug discovery via computational intelligence.

Hecht D, Fogel GB. Hecht D, et al. J Chem Inf Model. 2009 Apr;49(4):1105-21. doi: 10.1021/ci9000647. J Chem Inf Model. 2009. PMID: 19348414

6

QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives.

Hecht D, Cheung M, Fogel GB. Hecht D, et al. Biosystems. 2008 Apr;92(1):10-5. doi: 10.1016/j.biosystems.2007.10.005. Epub 2007 Nov 17. Biosystems. 2008. PMID: 18160210

7

Modeling the structural origins of drug resistance to isoniazid via key mutations in Mycobacterium tuberculosis catalase-peroxidase, KatG.

Marney MW, Metzger RP, Hecht D, Valafar F. Marney MW, et al. Among authors: hecht d. Tuberculosis (Edinb). 2018 Jan;108:155-162. doi: 10.1016/j.tube.2017.11.007. Epub 2017 Nov 22. Tuberculosis (Edinb). 2018. PMID: 29523317 Free PMC article.

8

Enhancing the selectivity of kinase inhibitors in oncology: a chemical biology perspective.

Maddox S, Hecht D, Gustafson JL. Maddox S, et al. Among authors: hecht d. Future Med Chem. 2016;8(3):241-4. doi: 10.4155/fmc.15.193. Epub 2016 Feb 22. Future Med Chem. 2016. PMID: 26898835 No abstract available.

9

Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors.

Smith DE, Marquez I, Lokensgard ME, Rheingold AL, Hecht DA, Gustafson JL. Smith DE, et al. Angew Chem Int Ed Engl. 2015 Sep 28;54(40):11754-9. doi: 10.1002/anie.201506085. Epub 2015 Aug 14. Angew Chem Int Ed Engl. 2015. PMID: 26276764

10

Structural-based analysis of dihydrofolate reductase evolution.

Hecht D, Tran J, Fogel GB. Hecht D, et al. Mol Phylogenet Evol. 2011 Oct;61(1):212-30. doi: 10.1016/j.ympev.2011.06.005. Epub 2011 Jun 17. Mol Phylogenet Evol. 2011. PMID: 21704717

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters